John Cox - 25 Mar 2024 Form 3/A Insider Report for Dyne Therapeutics, Inc. (DYN)

Reporting relationship: CEO & President, Director
Issuer ticker: DYN
Reported as of: 25 Mar 2024
Net transaction value: $0
SEC form: 3/A
Accepted by SEC: 04 Apr 2024, 21:07:38 UTC
Original report date: 27 Mar 2024
Prior SEC filing: 11 Aug 2023
Next SEC filing: 04 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Richard Scalzo, Attorney-in-Fact

Filing notes and source

Key filing fact

John Cox filed Form 3/A for Dyne Therapeutics, Inc. (DYN) on 04 Apr 2024.

Key facts

This page summarizes John Cox's Form 3/A filing for Dyne Therapeutics, Inc. (DYN).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Apr 2024, 21:07.

Change

Previous filing in this sequence was filed on 11 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3/A disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DYN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,000
Date: 25 Mar 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This Form 3/A is being filed to correct the number of shares of common stock reported in Table I of the original Form 3 filed on March 27, 2024, which inadvertently reported 10,000 shares of common stock beneficially owned by the reporting person instead of the 5,000 shares reported herein.